StockData
Revvity, Inc. logo

Revvity, Inc. (RVTY) KPIs and segments

RVTYNYSELaboratory Analytical InstrumentsFiscal year ends December 29
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jul 5, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3042% above fair value
$152.43+4.64 (+3.14%)

Close on Nov 18, 2026Market cap $17.01BP/E 72.6Yield 0.18%

KPI & bộ phận

Chỉ số vận hành và bộ phận làm nên hoạt động của Revvity · năm tài chính kết thúc ngày 31 tháng 12

Nhìn nhanh KPI của Revvity: 33 chỉ số vận hành, trong đó có Unbilled Software & Contract Receivables, Total Deferred Revenue và Customer Deposits (Recognized Within 3 Months), lấy từ 210 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.

Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.

Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.

Thêm vào biểu đồChỉ số
Q3 2026
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Diagnostics($M)3
371349390356354324355345343313210
Americas($M)
14213012912912712012511711811849.9
Europe($M)
14013113711911910610910711010175.4
Asia($M)
89.487.512410810998.212012111594.585.0
Life Sciences($M)3
359362382343366340375339349337486
Americas($M)
184186191178197184193185190177251
Europe($M)
89.591.799.983.384.376.088.175.174.677.5117
Asia($M)
85.684.690.781.484.580.193.378.284.282.5117
Product($M)
603581647573611563620580589549612
Service($M)
12613012512611010210910410310183.4
Americas($M)
326316320307324305319302308294301
Europe($M)
229223237202204182197182185179192
Asia($M)
175172214189193178213200199177202
Diagnostics($M)
11376.191.489.489.474.091.193.892.776.2
Life Sciences($M)
112104136101115106138111118101
Product($M)
339308344292325313349323326298332
Service($M)
77.879.577.982.167.463.063.661.459.456.951.1
Kỳ báo cáo trước đây (báo cáo lần cuối 2023)3
Unbilled Software & Contract Receivables($M)2
11210010710695.591.180.480.675.8
Current Unbilled Receivables (in Accounts Receivable)($M)
81.968.274.472.4
Long-Term Unbilled Receivables (in Other Assets)($M)
29.632.232.333.2
Total Deferred Revenue (SaaS, Maintenance & Prepaid Storage)($M)2
236240239225224225223213210
Current Deferred Revenue (Recognized Within 12 Months)($M)
170174172159
Long-Term Deferred Revenue (Beyond 12 Months)($M)
65.165.566.865.5
Customer Deposits (Recognized Within 3 Months)($M)
14.81620.319.319.51919.619.522.1
Signals Software Franchise Revenue($M)
67.557.761.862.352.367.853.961.843.350.744.945.6
Immunodiagnostics Franchise Revenue($M)4
202215202241213219198215212213189196
Diagnostics Pro Forma Organic Sales Growth (Ex-China IDX)(%)
5.0%11.0%9.0%
Diagnostics Legacy As-Reported Organic Sales Growth(%)
4.0%7.0%2.0%2.0%5.0%6.0%5.0%3.0%1.0%-6.0%
Diagnostics Foreign Exchange Revenue Impact(%)
-1.0%1.0%4.0%3.0%2.0%1.0%-2.0%-1.0%0.0%-1.0%-1.0%1.0%
Diagnostics Acquisitions & Divestitures Revenue Impact(%)
0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Reproductive Health Franchise Revenue($M)
147156147149143136127140134130125127
Legacy Applied Genomics Revenue (Reclassified to Life Sciences in FY2025)($M)
53.352.751.347.452.5
Finished Goods Inventory, Net($M)2
151140146138138138132128140132150162
Raw Materials Inventory, Net($M)
169167170173175181182175194198194197
Work-in-Process Inventory, Net($M)
68.971.871.56967.169.16865.27171.469.469.2
Life Sciences Solutions Franchise Revenue($M)6
312301300320291298287313296298292
Life Sciences Pro Forma Organic Sales Growth(%)
9.0%-3.0%3.0%
Life Sciences Legacy As-Reported Organic Sales Growth(%)
3.0%0.0%0.0%4.0%2.0%5.0%-3.0%-6.0%-8.0%-9.0%
Life Sciences Foreign Exchange Revenue Impact(%)
0.0%0.0%2.0%2.0%1.0%1.0%-1.0%0.0%0.0%-1.0%0.0%1.0%
Life Sciences Acquisitions & Divestitures Revenue Impact(%)
2.0%1.0%2.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Legacy Life Sciences Reagents Revenue (Pre-FY2025 Consolidation)($M)
186179177177179
Legacy Life Sciences Instruments Revenue (Pre-FY2025 Consolidation)($M)
88.178.886.380.995.3
Adjusted Operating Income (Continuing Operations)($M)9
209211168229182192170221194199166192
Adjusted Operating Margin (Continuing Operations)(%)
28.7%28.9%23.6%29.7%26.1%26.6%25.6%30.3%28.3%28.8%25.5%27.5%
GAAP Operating Margin (Continuing Operations)(%)
13.1%12.2%10.7%14.5%11.7%12.6%10.9%16.3%14.3%12.4%6.8%11.1%
Pro Forma Revenue (Ex-China Immunodiagnostics Divestiture)($M)
710711687661681629
Pro Forma Adjusted Operating Income (Ex-China IDX)($M)
209209165172180159
Pro Forma Adjusted Operating Margin (Ex-China IDX)(%)
29.4%29.3%24.0%26.0%26.5%25.3%
Pro Forma Organic Sales Growth (Continuing Operations)(%)
7.0%3.0%6.0%
Legacy As-Reported Organic Sales Growth (Continuing Operations)(%)
3.0%4.0%1.0%3.0%4.0%6.0%2.0%-1.0%-3.0%-8.0%
Foreign Exchange Impact on Consolidated Sales Growth(%)
-1.0%0.0%3.0%2.0%1.0%1.0%-1.0%-1.0%0.0%-1.0%0.0%1.0%
Acquisitions & Divestitures Impact on Consolidated Sales Growth(%)
1.0%1.0%1.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Adjusted Diluted EPS (Continuing Operations)($)7
1.381.411.061.701.181.181.011.421.281.220.981.25
Pro Forma Adjusted Diluted EPS (Ex-China IDX)($)
1.371.411.041.131.150.95
Full-Year Organic Sales Growth Guidance — Low Bound(%)
5.0%4.0%3.0%
Full-Year Organic Sales Growth Guidance — High Bound(%)
5.0%5.0%4.0%
Full-Year Revenue Guidance — Low Bound($M)
2,8602,8302,810
Full-Year Revenue Guidance — High Bound($M)
2,8602,8602,840
Full-Year Adjusted Diluted EPS Guidance — Low Bound($)
5.405.305.20
Full-Year Adjusted Diluted EPS Guidance — High Bound($)
5.455.405.30
Free Cash Flow Conversion (% of Adjusted Net Income)(%)4
99.0%117.0%97.0%84.0%
Free Cash Flow (Management-Reported)($M)
152184115162
Net Debt to Adjusted EBITDA Leverage Ratio(×)
2.302.502.80
Adjusted Net Interest & Other Expense($M)
21222323
Adjusted Effective Tax Rate(%)
18.0%16.0%18.3%6.5%
Life Sciences — Segment Cost of Revenue($M)4
136127132132130135119127118120124
Life Sciences — Segment SG&A Expenses($M)
96.393.894.786.284.28787.183.784.984.285.9
Life Sciences — Segment R&D Expenses($M)
27.926.431.627.727.628.428.326.225.726.426.1
Life Sciences — Segment Depreciation Expense($M)
9.308.209.909.308.508.507.205.108.708.108.30
Life Sciences — Segment Adjusted Operating Margin(%)
31.5%31.1%28.7%29.5%31.6%31.1%
Diagnostics — Segment Cost of Revenue($M)4
140151157184159156135154145146131
Diagnostics — Segment SG&A Expenses($M)
85.184.790.284.784.784.189.986.384.183.182.6
Diagnostics — Segment R&D Expenses($M)
20.122.626.230.423.124.825.322.822.62123.5
Diagnostics — Segment Depreciation Expense($M)
8.508.509.609.508.808.306.8011.58.8087.70
Diagnostics — Segment Adjusted Operating Margin(%)
29.9%30.4%21.8%25.1%25.2%22.8%
Unallocated Corporate Operating Expenses($M)1
14.513.412.2-2813.19.80810.911.411.4
Corporate Headquarters Depreciation Expense($M)
0.400.400.500.800.700.700.700.600.500.600.60
Remaining Share Repurchase Program Authorization($M)2
793793801880210415857355
Common Shares Repurchased in Quarter (All Programs)
80694,873835,2571,763,2952,324,3513,103,9301,561,18345,905
Average Price Paid Per Repurchased Share($)
11884.0110195.4288.2094.34116108
Finite-Lived Intangible Assets, Net($M)5
2,1382,2242,3072,3472,4262,5142,5712,6412,7632,8262,9193,022
Intangible Asset Amortization Expense($M)
84.784.985.183.584.185.382.787.989.690.691.289.6
Scheduled Intangible Amortization — Next 12 Months / Year 1($M)
313313313332332333328332337333333363
Scheduled Intangible Amortization — Year 2($M)
287287287305305305301326331327327335
Scheduled Intangible Amortization — Year 3($M)
257257257279279279275299304300300329
Scheduled Intangible Amortization — Year 4($M)
228228228249249250246273278274275302
Property, Plant & Equipment Gross — Machinery & Equipment1
Total Depreciation Expense($M)
18.217.22019.61817.514.717.21816.716.6
Restructuring Reserve Liability($M)1
4532.81417.83.80
Environmental Loss Contingency Accrual($M)
10.610.610.710.811.111.111.914.214.514.514.414.1
FDA 510(k) Premarket Clearances — Revvity Group5
100000000000
FDA PMA Approvals & Supplements — Revvity Group
000020200212
FDA Medical Device Recalls Posted — Revvity Group
100000000000
FDA MAUDE Adverse Event Reports — Revvity Group
001101000000
U.S. Medical Device Industry Total — FDA 510(k) Clearances
856923756806797886736856767793713877
U.S. Medical Device Industry Total — FDA PMA Approvals & Supplements
565608567525585588524683538550459656
Consolidated Revenue($M)5
729730711772699720665729684692650696
Operating Income (Continuing Operations)($M)
95.189.375.911281.990.872.211998.285.744.177.2
Research & Development Expense($M)
48.14957.958.250.853.353.649.249.148.150.449.6
Selling, General & Administrative Expense($M)
275279254252242249250244238252261257
Income from Continuing Operations($M)
62.653.540.995.847.255.241.788.493.472.628.763.6
Consolidated Net Income($M)
62.351.840.798.446.753.942.294.694.455.42678.6
Cash & Cash Equivalents($M)8
5931,0238609209319921,1381,1651,2301,248998913
Accounts Receivable, Net($M)
687709691745680661617632602597589633
Inventories, Net($M)
389379388380380389381368405401414428
Property, Plant & Equipment, Net($M)
451456466479497499487482518503504510
Goodwill($M)
6,5886,6086,6116,6146,6016,6156,5126,4646,5596,4976,5046,534
Intangible Assets, Net($M)
2,1382,2242,3072,3472,4262,5142,5712,6412,7632,8262,9193,022
Total Assets($M)
11,49012,04611,99712,16812,13912,36312,36112,39312,77013,42513,43313,565
Long-Term Debt($M)
2,6342,6332,6322,6312,6313,2143,1683,1513,1863,1633,1653,178
Total Stockholders' Equity($M)
7,2717,2297,1837,2507,3767,5567,6377,6677,9227,8707,8477,873
Operating Cash Flow($M)4
167192115182139134128174148159148197
Capital Expenditures($M)
14.311.119.820.218.518.91624.522.32217.824.1
Common Stock Repurchases (Cash Outflow)($M)
0.101686.516820529415418515419.610.84.90
Common Stock Dividends Paid($M)
7.807.807.8088.108.308.408.508.608.608.608.60
Stock-Based Compensation Expense($M)
9.8010.78.70-4.109.1010.17.705.1010.510.511.77.20

19 chỉ số không có số liệu trong 12 quý gần nhất — .

In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).

Phương pháp và các chỉ số bị loại
  • Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
  • Revvity, Inc. (formerly PerkinElmer, Inc. prior to May 2023) operates on a 52/53-week fiscal year ending on the Sunday nearest December 31; the latest completed company period is Q3 2026 (ended October 4, 2026).
  • On July 31, 2026, Revvity signed a definitive agreement to divest its Immunodiagnostics business in China ('China IDX', ~6% of FY2025 revenue); beginning in 2026 earnings releases, management reports headline organic growth and forward guidance on a Pro Forma basis excluding China IDX.
  • In Q1 2025, Revvity integrated Applied Genomics (previously in Diagnostics) into Life Sciences Solutions and reclassified prior periods back to FY2023; legacy pre-reclassification sub-lines are preserved as collapsed historical series through Q4 2024.
  • Only cumulative-to-period derivations (Q4 = full year minus nine months from matching restatement vintages; quarterly cash flow = year-to-date minus prior year-to-date) are computed. Consolidated-minus-parent disaggregation is not applicable under consolidated US GAAP reporting.
  • Independent external monthly indicators (openFDA device/IVD clearances, USAspending.gov federal prime contract obligations, and BLS Producer Price Indices for NAICS 334516/325413/621511) include October 2026 observations ahead of Q4 2026 corporate results.

Không hiện vì thiếu các kỳ gần đây (7)

  • Top-level Life Sciences & Diagnostics Segment Revenue, Segment Profit, Regional Revenue (Americas, Europe, Asia), and Product vs. Service Revenue: omitted from custom sheet because XBRL segment series are already displayed natively in Core view
  • Transaction Price Allocated to Remaining Performance Obligations (RPO): Revvity elects the ASC 606 practical expedient for contracts <=1 year and states that unsatisfied RPO >1 year is immaterial (not numerically disclosed)
  • Oxford Immunotec Limited (UK Companies House #04516079) Audited Statutory Series (FY2020–FY2024): latest filed UK statutory accounts cover through December 29, 2024; FY2025 accounts are not yet due at Companies House (missing FY2025 for two-year continuity)
  • Signals Software ARR (>$100M in 2026E), APV (>$130M in 2020; >$275M in 2026E), Active Users (1M+), Customers (4,000+), Cumulative Babies Screened (>868M), and Compliance Training Completion (>98% / >99%): excluded because disclosed only as inequality bounds rather than exact point figures
  • Initial FY2025 Scope 3 Greenhouse Gas Emissions Breakdown (103,453 tCO2e across 6 categories in 2026 Impact Report): first disclosed for baseline year 2025 only (single annual observation, lacks two consecutive years)
  • Global Babies Screened Annually (~40M/year): stated qualitatively as a multi-year rounded benchmark in narrative Impact Report highlights rather than an audited annual time-series table through FY2025
  • U.S. Producer Price Index — Analytical Laboratory Instrument Manufacturing (NAICS 334516) › U.S. Medical & Diagnostic Laboratories Industry Revenue (Census QSS): lacks continuous multi-period coverage through latest reporting period

Dữ liệu cập nhật 2026-11-18.

Mỗi KPI một trang riêng

Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số

Life Sciences Solutions Franchise & Manufacturing Inventory Pipeline (Key #3)

Tài liệu nguồn mới nhất

Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Revvity

See a number that looks wrong?